Mary Ellen Dwyer
Staff Affiliate - YNHHCards
About
Research
Publications
2024
Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology.
Hodan R, Gupta S, Weiss J, Axell L, Burke C, Chen L, Chung D, Clayback K, Felder S, Foda Z, Giardiello F, Grady W, Gustafson S, Hagemann A, Hall M, Hampel H, Idos G, Joseph N, Kassem N, Katona B, Kelly K, Kieber-Emmons A, Kupfer S, Lang K, Llor X, Markowitz A, Prats M, Niell-Swiller M, Outlaw D, Pirzadeh-Miller S, Samadder N, Shibata D, Stanich P, Swanson B, Szymaniak B, Welborn J, Wiesner G, Yurgelun M, Dwyer M, Darlow S, Diwan Z. Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 695-711. PMID: 39689429, DOI: 10.6004/jnccn.2024.0061.Peer-Reviewed Original ResearchConceptsMultigene panel testingPathogenic/likely pathogenic variantsGenetic/Familial High-Risk AssessmentColon cancer screeningColon cancer riskHigh risk of cancerNCCN Clinical Practice GuidelinesClinical practice guidelinesRisk of cancerPanel testingHigh riskPathogenic variantsPeutz-Jeghers syndromeLynch syndromeCancer screeningDe-implementationCancer riskEndometrial cancerPTEN hamartoma tumor syndromeHigh-risk assessmentPractice guidelinesHamartoma tumor syndromePeutz-JeghersNCCN GuidelinesCHEK2Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, Brander D, Cortese M, Cripe L, Davis R, Eradat H, Fakhri B, Fletcher C, Gaballa S, Hamid M, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps T, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens D, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach J, Sundar H, Dwyer M. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 175-204. PMID: 38626800, DOI: 10.6004/jnccn.2024.0018.Peer-Reviewed Original ResearchConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaPredictor of improved survivalUndetectable minimal residual diseaseImmunoglobulin heavy chain variable region mutational statusMinimal residual diseaseManagement of patientsSelection of treatmentRelapsed/refractory CLL/SLLLymphocytic lymphomaResidual diseaseCombination regimensTP53 mutationsMutation statusPerformance statusLymphocytic leukemiaNCCN GuidelinesPatient agePrognostic implicationsToxicity profileDisease stageComorbid conditionsPatientsCLL/SLLCytogenetic variability
2023
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N, Budde L, Caimi P, Chang J, Christian B, DeVos S, Dholaria B, Fayad L, Habermann T, Hamid M, Hernandez-Ilizaliturri F, Hu B, Kaminski M, Karimi Y, Kelsey C, King R, Krivacic S, LaCasce A, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts K, Saeed H, Smith S, Svoboda J, Swinnen L, Tuscano J, Vose J, Dwyer M, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 1118-1131. PMID: 37935098, DOI: 10.6004/jnccn.2023.0057.Peer-Reviewed Original ResearchConceptsB-cell lymphomaMantle cell lymphomaCAR T-cell therapyT-cell therapyTyrosine kinase inhibitorsFollicular lymphomaNCCN guidelinesAnti-CD19 CAR T-cell therapyRefractory B-cell lymphomaTreatment of FLBispecific T-cell engagersBruton tyrosine kinase inhibitorsLarge B-cell lymphomaNCCN Guidelines InsightsRefractory follicular lymphomaNovel immunotherapeutic approachesRelapsed Follicular LymphomaT-cell engagersTreatment landscapeImmunotherapeutic approachesFrontline settingTreatment optionsCell lymphomaLymphomaTherapy
2018
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
Flaig T, Spiess P, Agarwal N, Bangs R, Boorjian S, Buyyounouski M, Downs T, Efstathiou J, Friedlander T, Greenberg R, Guru K, Hahn N, Herr H, Hoimes C, Inman B, Jimbo M, Kader A, Lele S, Meeks J, Michalski J, Montgomery J, Pagliaro L, Pal S, Patterson A, Petrylak D, Plimack E, Pohar K, Porter M, Preston M, Sexton W, Siefker-Radtke A, Tward J, Wile G, Johnson-Chilla A, Dwyer M, Gurski L. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 1041-1053. PMID: 30181416, DOI: 10.6004/jnccn.2018.0072.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAftercareBCG VaccineChemotherapy, AdjuvantCystectomyHumansLymphatic MetastasisMedical OncologyNeoadjuvant TherapyNeoplasm StagingOrgan Sparing TreatmentsPatient SelectionQuality of LifeRadiotherapy, AdjuvantRandomized Controlled Trials as TopicSocieties, MedicalTreatment OutcomeUnited StatesUrinary Bladder NeoplasmsConceptsBladder cancerTreatment of muscle-invasive bladder cancerImmune checkpoint inhibitor therapyMuscle-invasive bladder cancerNCCN Clinical Practice GuidelinesFollow-up of patientsAJCC Cancer Staging ManualCheckpoint inhibitor therapyCancer Staging ManualNCCN Guidelines InsightsClinical practice guidelinesMetastatic diseaseInhibitor therapyStaging ManualTreatment optionsFollow-upCancerBladderPractice guidelinesPatientsNCCNTreatmentAJCCTherapyGuidelinesNCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018.
Provenzale D, Gupta S, Ahnen D, Markowitz A, Chung D, Mayer R, Regenbogen S, Blanco A, Bray T, Cooper G, Early D, Ford J, Giardiello F, Grady W, Hall M, Halverson A, Hamilton S, Hampel H, Klapman J, Larson D, Lazenby A, Llor X, Lynch P, Mikkelson J, Ness R, Slavin T, Sugandha S, Weiss J, Dwyer M, Ogba N. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 939-949. PMID: 30099370, DOI: 10.6004/jnccn.2018.0067.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBiomarkers, TumorColonoscopyColorectal NeoplasmsDNA, NeoplasmEarly Detection of CancerFecesHumansImmunochemistryMass ScreeningMedical OncologyMiddle AgedOccult BloodRandomized Controlled Trials as TopicSeptinsSocieties, MedicalTime FactorsTomography, X-Ray ComputedUnited StatesConceptsColorectal cancerNCCN GuidelinesRecommended screening strategySporadic colorectal cancerAverage-riskNCCN panelScreening modalitiesNCCN Guidelines InsightsScreening individualsIncreased-riskScreening strategiesNCCNGuidelinesRelevant dataIndividualsColorectalModalitiesPrimary focusScreeningRecommendationsReview commentsCancerFocusNCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.
Horwitz S, Ansell S, Ai W, Barnes J, Barta S, Choi M, Clemens M, Dogan A, Greer J, Halwani A, Haverkos B, Hoppe R, Jacobsen E, Jagadeesh D, Kim Y, Lunning M, Mehta A, Mehta-Shah N, Oki Y, Olsen E, Pro B, Rajguru S, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer M, Sundar H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 123-135. PMID: 29439173, DOI: 10.6004/jnccn.2018.0007.Peer-Reviewed Original ResearchConceptsExtranodal NK/T-cell lymphomaNK/T-cell lymphomaNatural killer (NK)/T-cell lymphomaSubtype of non-Hodgkin lymphomaNon-Hodgkin's lymphomaT-cell lymphomaNCCN Guidelines InsightsUpper aerodigestive tractManagement of patientsNasal typeNK/T-cellRare malignancyStandard therapyNCCN GuidelinesAerodigestive tractT cellsLymphomaRandomized trialsPatientsNCCNMalignancyRegimensTherapySubtypesDiagnosis
2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
Wierda W, Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis C, Bartlett N, Byrd J, Caimi P, Fayad L, Fisher R, Glenn M, Habermann T, Harris N, Hernandez-Ilizaliturri F, Hoppe R, Horwitz S, Kaminski M, Kelsey C, Kim Y, Krivacic S, LaCasce A, Martin M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad A, Snyder E, Sokol L, Swinnen L, Vose J, Yahalom J, Dwyer M, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. Journal Of The National Comprehensive Cancer Network 2017, 15: 293-311. PMID: 28275031, DOI: 10.6004/jnccn.2017.0030.Peer-Reviewed Original ResearchConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaTreatment of patientsNCCN Clinical Practice GuidelinesCD20 monoclonal antibodyNCCN Guidelines InsightsClinical practice guidelinesRelapsed/refractory CLL/SLLChemoimmunotherapy regimensLymphocytic lymphomaCritical signaling pathwaysLymphocytic leukemiaSmall molecule inhibitorsCLL/SLLBcl-2 familyBcl-2Monoclonal antibodiesMolecule inhibitorsSignaling pathwayPractice guidelinesPatientsNCCNTreatmentLymphomaRegimens
2016
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Daly M, Pilarski R, Berry M, Buys S, Farmer M, Friedman S, Garber J, Kauff N, Khan S, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Merajver S, Offit K, Pal T, Reiser G, Shannon K, Swisher E, Vinayak S, Voian N, Weitzel J, Wick M, Wiesner G, Dwyer M, Darlow S. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. Journal Of The National Comprehensive Cancer Network 2016, 15: 9-20. PMID: 28040716, DOI: 10.6004/jnccn.2017.0003.Peer-Reviewed Original ResearchConceptsGenetic/Familial High-Risk AssessmentHigh-risk assessmentOvarian cancerNCCN Clinical Practice GuidelinesNCCN Guidelines InsightsClinical practice guidelinesRisk of breastHereditary cancer syndromesPenetrant genetic mutationsMost recent recommendationsRelevant new dataPractice guidelinesCancer syndromesGenetic testingBreastSyndromeRecent recommendationsGenetic mutationsCancerManagement recommendationsRisk management recommendationsGuidelinesAssessmentPatientsRecommendationsGenetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
Daly M, Pilarski R, Axilbund J, Berry M, Buys S, Crawford B, Farmer M, Friedman S, Garber J, Khan S, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom P, Merajver S, Offit K, Pal T, Rana H, Reiser G, Robson M, Shannon K, Swisher E, Voian N, Weitzel J, Whelan A, Wick M, Wiesner G, Dwyer M, Kumar R, Darlow S. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. Journal Of The National Comprehensive Cancer Network 2016, 14: 153-62. PMID: 26850485, DOI: 10.6004/jnccn.2016.0018.Peer-Reviewed Original ResearchConceptsGenetic/Familial High-Risk AssessmentHigh-risk assessmentOvarian cancer risk reductionGenetic testing criteriaNCCN Guidelines InsightsCancer risk reductionRisk of breastHereditary cancer syndromesCommon genetic mutationsOvarian cancer histologiesNCCN guidelinesMultigene testingPancreatic cancerOvarian cancerCancer histologyCancer syndromesGenetic testingBreastPanel meetingGenetic mutationsPersonal historySyndromeRisk reductionCancerManagement recommendations